Daniel Bessesen
Endocrinology, Diabetes & Metabolism · Denver, CONPI 1447262506
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Eli Lilly at 59.4% of the total. 2025 is the largest year on record at $17,634, more than ten times the $14 reported in 2020.
Across 43 payments — averaging $788.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$20K
- Novo Nordisk$7K
- Lilly USA, LLC$4K
- Novo Nordisk US Research & Development, Inc.$2K
- Chiesi USA, Inc.$325
- Insulet Corporation$14
Across 27 payments — averaging $41,903 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1M
- Pfizer$86K
What the payments were for
- Consulting fees$19,67058%
- Speaking & faculty fees$3251%
- Travel & lodging$3,0419%
- Food & beverage$10,86232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 32 | $20,145 |
| Novo Nordisk | 5 | $7,229 |
| Lilly USA, LLC | 3 | $4,485 |
| Novo Nordisk US Research & Development, Inc. | 1 | $1,700 |
| Chiesi USA, Inc. | 1 | $325 |
| Insulet Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYALEPT$325
How this compares
$33,898 in reported general payments places this provider in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 13 | $531,233 |
| TrulicityDulaglutide | 19 | $22,401 |
| Teriparatide | 15 | $18,622 |
| OzempicSemaglutide | 13 | $5,604 |
| Insulin Aspart FlexpenInsulin Aspart | 12 | $987 |
| Levothyroxine Sodium | 25 | $324 |
| Atorvastatin Calcium | 12 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $4,485 | $22,40119 claims |
| Novo NordiskOzempic | $7,229 | $5,60413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Denver
- Michael LoughnerDenver$32K
- Leonard ZemelDenver$19K
- Alex GoldsmithDenver$12K
- Daniel CitronDenver$8K
- Sarah BullDenver$4K
- Leslie GamacheDenver$4K
- Claudia PanzerDenver$3K
- Sheila MaierDenver$2K
- Karin HickeyDenver$2K
- Gregory LundDenver$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.